237 related articles for article (PubMed ID: 38546648)
1. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020.
Sherry AD; Hahn AW; McCaw ZR; Abi Jaoude J; Kouzy R; Lin TA; Minsky B; Fuller CD; Meirson T; Msaouel P; Ludmir EB
JAMA Netw Open; 2024 Mar; 7(3):e243379. PubMed ID: 38546648
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020.
Paratore C; Zichi C; Audisio M; Bungaro M; Caglio A; Di Liello R; Gamba T; Gargiulo P; Mariniello A; Reale ML; Perrone F; Di Maio M
ESMO Open; 2022 Dec; 7(6):100593. PubMed ID: 36228332
[TBL] [Abstract][Full Text] [Related]
4. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
[TBL] [Abstract][Full Text] [Related]
5. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
Zhang S; Liang F; Li W; Hu X
J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
[TBL] [Abstract][Full Text] [Related]
6. Credibility of claims of subgroup effects in randomised controlled trials: systematic review.
Sun X; Briel M; Busse JW; You JJ; Akl EA; Mejza F; Bala MM; Bassler D; Mertz D; Diaz-Granados N; Vandvik PO; Malaga G; Srinathan SK; Dahm P; Johnston BC; Alonso-Coello P; Hassouneh B; Walter SD; Heels-Ansdell D; Bhatnagar N; Altman DG; Guyatt GH
BMJ; 2012 Mar; 344():e1553. PubMed ID: 22422832
[TBL] [Abstract][Full Text] [Related]
7. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.
Sherry AD; Msaouel P; Kouzy R; Abi Jaoude J; Lin TA; Taniguchi CM; Fuller CD; Minsky B; Ludmir EB
Oncologist; 2024 Jun; ():. PubMed ID: 38824414
[TBL] [Abstract][Full Text] [Related]
8. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Addeo A; Weiss GJ; Gyawali B
JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
[TBL] [Abstract][Full Text] [Related]
9. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.
Jenei K; Raymakers A; Meyers DE; Prasad V
J Cancer Policy; 2021 Dec; 30():100311. PubMed ID: 35559802
[TBL] [Abstract][Full Text] [Related]
10. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
11. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
12. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
[TBL] [Abstract][Full Text] [Related]
13. Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials.
Khan MS; Khan MAA; Irfan S; Siddiqi TJ; Greene SJ; Anker SD; Sreenivasan J; Friede T; Tahhan AS; Vaduganathan M; Fonarow GC; Butler J
ESC Heart Fail; 2021 Feb; 8(1):26-36. PubMed ID: 33254286
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation and nonpublication of clinical trials in orthopaedic oncology.
Singh G; Wague A; Arora A; Rao V; Ward D; Barry J
J Orthop Surg Res; 2024 Feb; 19(1):121. PubMed ID: 38317223
[TBL] [Abstract][Full Text] [Related]
15. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study.
Toews I; Anglemyer A; Nyirenda JL; Alsaid D; Balduzzi S; Grummich K; Schwingshackl L; Bero L
Cochrane Database Syst Rev; 2024 Jan; 1(1):MR000034. PubMed ID: 38174786
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
17. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials.
Florez MA; Jaoude JA; Patel RR; Kouzy R; Lin TA; De B; Beck EJ; Taniguchi CM; Minsky BD; Fuller CD; Lee JJ; Kupferman M; Raghav KP; Overman MJ; Thomas CR; Ludmir EB
JAMA Netw Open; 2023 May; 6(5):e2313819. PubMed ID: 37195664
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
